title: High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients. A randomized trial.
abstract: OBJECTIVE
  To assess the efficacy of high-dose oral acyclovir therapy compared with preemptive, short-course ganciclovir therapy (administered only if cytomegalovirus [CMV] shedding occurred) to prevent CMV disease in liver transplant recipients.
  
  
  METHODS
  A randomized controlled trial.
  
  
  METHODS
  Liver transplant center at a university-affiliated Veterans Affairs Medical Center.
  
  
  METHODS
  47 consecutive patients having liver transplantation.
  
  
  METHODS
  Patients were stratified by their CMV antibody status and the CMV antibody status of the donor and were randomly assigned to one of two treatment groups. Surveillance cultures for CMV (buffy coat and urine) were done every 2 to 4 weeks for 24 weeks in all patients. One group received high-dose oral acyclovir (800 mg four times daily). The experimental group received no acyclovir, but if surveillance cultures were positive, ganciclovir (5 mg/kg intravenously twice daily) was administered for 7 days.
  
  
  METHODS
  Cytomegalovirus shedding and CMV disease were measured in the two groups.
  
  
  RESULTS
  Cytomegalovirus shedding before the onset of CMV disease occurred in 25% (6 of 24) of patients in the acyclovir group compared with 22% (5 of 23) in the experimental group. Cytomegalovirus disease developed in 29% (7 of 24) of the acyclovir group and in 4% (1 of 23) of the experimental group (P < 0.05). No hematologic toxicity occurred with ganciclovir.
  
  
  CONCLUSIONS
  Oral acyclovir is ineffective prophylaxis against CMV in liver transplant recipients. Preemptive, short-course ganciclovir therapy in patients with CMV shedding was well tolerated and provided effective prophylaxis against subsequent CMV disease; this protocol targets the patients at risk for CMV disease and minimizes toxicity and expense.
authors.affiliation: Veterans Affairs Medical Center, Pittsburgh, Pennsylvania.
authors.forename: N
authors.initials: N
authors.lastname: Singh
authors.forename: V L
authors.initials: VL
authors.lastname: Yu
authors.forename: L
authors.initials: L
authors.lastname: Mieles
authors.forename: M M
authors.initials: MM
authors.lastname: Wagener
authors.forename: R C
authors.initials: RC
authors.lastname: Miner
authors.forename: T
authors.initials: T
authors.lastname: Gayowski
mesh_terms: D000212:Acyclovir / Q000008:administration & dosage* / Q000009:adverse effects; D000328:Adult; D000368:Aged; D003586:Cytomegalovirus Infections / Q000382:microbiology / Q000517:prevention & control*; D004334:Drug Administration Schedule; D015774:Ganciclovir / Q000008:administration & dosage*; D006085:Graft Survival; D006561:Herpes Simplex / Q000188:drug therapy; D006801:Humans; D016031:Liver Transplantation / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000401:mortality; D018139:Simplexvirus; D013997:Time Factors; D017201:Virus Shedding
chemical_list: D015774:Ganciclovir; D000212:Acyclovir